Enurace 50, 50 mg Tablets for Dogs

This product is not suitable for treatment of inappropriate urination due to behaviour
problems.

Revised: November 2020
AN: 00751/2020
Special precautions for use in animals
Do not use the product in dogs under 20 kilogram of bodyweight.
As ephedrine is an alpha- and beta-adrenergic receptor agonist, the product should
be used with caution in dogs with cardiovascular disease and only after a
comprehensive risk/benefit analysis by the attending veterinarian.
The dog’s cardiovascular functionality should be carefully assessed before the start
of the treatment with the product and it should be periodically monitored during the
treatment.
In addition, a similar approach should be adopted in animals suffering from partial
urethral obstruction, hypertension, diabetes mellitus, hyperadrenocorticism,
hyperthyroidism or other metabolic disorders. It should be mentioned that the
polyuria/polydipsia (PU/PD) frequently accompanying the aforementioned conditions
may be falsely diagnosed as urinary incontinence.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals
Ephedrine hydrochloride could be toxic if ingested. Adverse effects may include
insomnia and nervousness, dizziness, headache, increased blood pressure,
increased sweating and nausea.
Ingestion may be fatal, especially in children. To avoid accidental ingestion, the
product must be used and kept out of the reach of children. Always replace the cap
securely after use.
In case of accidental ingestion, most importantly by children, seek medical advice
immediately and show the package leaflet or the label to the physician.
It is strongly recommended that pregnant women should wear gloves for
administration.
Wash hands after administration.